dc.contributor.author | Barrero Hernández, Francisco Javier | |
dc.contributor.author | Mallada-Frechin, J | |
dc.contributor.author | Martínez-Ginés, ML | |
dc.contributor.author | Marzo, ME | |
dc.contributor.author | Meca-Lallana, V | |
dc.contributor.author | Izquierdo, G | |
dc.contributor.author | Ara, JR | |
dc.contributor.author | Oreja-Guevara, C | |
dc.contributor.author | Meca-Lallana, J | |
dc.contributor.author | Forero, L | |
dc.contributor.author | Sánchez-Vera, I | |
dc.contributor.author | Moreno, MJ | |
dc.date.accessioned | 2024-09-04T07:57:19Z | |
dc.date.available | 2024-09-04T07:57:19Z | |
dc.date.issued | 2020-04 | |
dc.identifier.citation | Barrero F, Mallada-Frechin J, Martínez-Ginés ML, Marzo ME, Meca-Lallana V, Izquierdo G, Ara JR, Oreja-Guevara C, Meca-Lallana J, Forero L, Sánchez-Vera I, Moreno MJ; in representation of the MS NEXT study investigators. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study. PLoS One. 2020 Apr 2;15(4):e0230846. doi: 10.1371/journal.pone.0230846. PMID: 32240213; PMCID: PMC7117743. | es_ES |
dc.identifier.uri | https://hdl.handle.net/10481/93891 | |
dc.language.iso | eng | es_ES |
dc.publisher | PLOS | es_ES |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study | es_ES |
dc.type | journal article | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.1371/journal.pone.0230846. | |
dc.type.hasVersion | AM | es_ES |